Intuitive Surgical, Inc. (NASDAQ:ISRG) Receives $509.02 Consensus Price Target from Brokerages

Posted by Francis Steltz on Aug 3rd, 2026

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the twenty-nine brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and twenty have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $509.0169.

A number of equities analysts recently issued reports on the stock. Royal Bank Of Canada decreased their price target on shares of Intuitive Surgical from $650.00 to $600.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Weiss Ratings reiterated a “hold (c)” rating on shares of Intuitive Surgical in a report on Tuesday, May 19th. The Goldman Sachs Group set a $558.00 target price on Intuitive Surgical in a report on Wednesday, May 27th. JPMorgan Chase & Co. decreased their target price on Intuitive Surgical from $550.00 to $450.00 and set an “overweight” rating for the company in a research report on Friday, July 17th. Finally, Citigroup lowered their target price on Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a research note on Friday, July 17th.

View Our Latest Research Report on Intuitive Surgical

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

Positive Sentiment: UBS upgraded ISRG, arguing that the recent selloff was excessive. The firm’s revised price target of $475 implies meaningful upside and may be supporting renewed investor interest. UBS upgrades Intuitive Surgical
Positive Sentiment: Intuitive Surgical’s expansion beyond urology into general surgery and other specialties could create additional procedure growth and increase long-term demand for da Vinci systems, instruments and related services. Robotic surgery expansion beyond urology
Positive Sentiment: Analyst sentiment remains broadly favorable, with the brokerage consensus at “Moderate Buy.” The company’s recurring revenue from instruments and accessories, expanding installed base and durable robotic-surgery demand remain key bullish arguments. Brokerage consensus on Intuitive Surgical
Neutral Sentiment: Zacks highlighted the unusually high level of investor interest in ISRG, but the article did not provide a new earnings or guidance catalyst. Zacks investor attention report
Neutral Sentiment: An executive’s small stock sales were made under a pre-arranged Rule 10b5-1 plan and reduced his holdings by roughly 2%, making them unlikely to materially alter the investment case. Intuitive Surgical insider sale
Negative Sentiment: HSBC lowered Intuitive Surgical from Buy to Hold and set a $391 price target. Although that target remains above recent trading levels, the downgrade signals reduced confidence in the stock’s near-term upside. HSBC downgrades Intuitive Surgical
Negative Sentiment: Despite a quarterly revenue and earnings beat, investors remain concerned about softer U.S. procedure growth, deferred care and the premium valuation. Those worries have contributed to continued pressure in the shares. Intuitive Surgical post-earnings selloff

Insiders Place Their Bets

In other news, SVP Iman Jeddi sold 5,625 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $420.55, for a total value of $2,365,593.75. Following the sale, the senior vice president directly owned 6,463 shares of the company’s stock, valued at $2,718,014.65. This represents a 46.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of the company’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $424.14, for a total transaction of $169,656.00. Following the completion of the sale, the executive vice president directly owned 5,720 shares in the company, valued at $2,426,080.80. This represents a 6.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 6,634 shares of company stock valued at $2,796,795. 0.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Intuitive Surgical

Several hedge funds have recently bought and sold shares of ISRG. Newbridge Financial Services Group Inc. lifted its holdings in shares of Intuitive Surgical by 300.0% during the fourth quarter. Newbridge Financial Services Group Inc. now owns 44 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 33 shares during the last quarter. Main Street Group LTD purchased a new stake in shares of Intuitive Surgical in the 1st quarter worth approximately $30,000. Laurel Wealth Advisors LLC purchased a new stake in shares of Intuitive Surgical in the 4th quarter worth approximately $31,000. Vermillion Wealth Management Inc. increased its position in Intuitive Surgical by 58.1% during the 1st quarter. Vermillion Wealth Management Inc. now owns 68 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 25 shares in the last quarter. Finally, Turning Point Benefit Group Inc. increased its position in Intuitive Surgical by 833.3% during the 4th quarter. Turning Point Benefit Group Inc. now owns 56 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 50 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $353.33 on Friday. Intuitive Surgical has a 12-month low of $328.57 and a 12-month high of $603.88. The company has a market cap of $124.82 billion, a P/E ratio of 40.47, a PEG ratio of 2.55 and a beta of 1.47. The company’s fifty day simple moving average is $398.27 and its two-hundred day simple moving average is $451.13.

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last posted its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, topping the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The firm had revenue of $2.89 billion during the quarter, compared to analysts’ expectations of $2.83 billion. During the same period last year, the company posted $1.81 EPS. The company’s quarterly revenue was up 18.4% compared to the same quarter last year. Analysts predict that Intuitive Surgical will post 8.87 EPS for the current fiscal year.

About Intuitive Surgical

(Get Free Report)

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.